Telmisartan prevents proliferation and promotes apoptosis of human ovarian cancer cells through upregulating PPARγ and downregulating MMP-9 expression

Molecular Medicine Reports

Volumn 13, Issue 1, 2016, Pages 555-559

  Pu, Zhichen ^a,b   Zhu, Min ^a   Kong, Fandou ^a  

^a DALIAN MEDICAL UNIVERSITY   (China)

^b WANNAN MEDICAL COLLEGE   (China)

Author keywords

Matrix metalloproteinase 9; Ovarian cancer; Peroxisome proliferator activated receptor ; Telmisartan

Indexed keywords

CASPASE 3; FLUORESCEIN ISOTHIOCYANATE; GELATINASE B; LIPOCORTIN 5; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROPIDIUM IODIDE; SMALL INTERFERING RNA; TELMISARTAN; BENZIMIDAZOLE DERIVATIVE; BENZOIC ACID DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MTT ASSAY; OVARY CANCER; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; ZYMOGRAPHY; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECTS; ENZYMOLOGY; METABOLISM; OVARY TUMOR; PATHOLOGY;

APOPTOSIS; BENZIMIDAZOLES; BENZOATES; CELL PROLIFERATION; DOWN-REGULATION; FEMALE; FLOW CYTOMETRY; HUMANS; MATRIX METALLOPROTEINASE 9; OVARIAN NEOPLASMS; PPAR GAMMA; RNA, SMALL INTERFERING; UP-REGULATION;

EID: 84954306776     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2015.4512     Document Type: Article

References (34)

1. Kamangar F, Dores GM and Anderson WF: Patterns of cancer incidence, mortality and prevalence across five continents: Defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24: 2137-2150, 2006.
2. Des Jarlais G, Kaplan CP, Haas JS, Gregorich SE, Perez-Stable EJ and Kerlikowske K: Factors affecting participation in a breast cancer risk reduction telephone survey among women from four racial/ethnic groups. Prev Med 41: 720-727, 2005.
3. Salehi F, Dunfield L, Phillips KP, Krewski D and Vanderhyden BC: Risk factors for ovarian cancer: An overview with emphasis on hormonal factors. J Toxicol Environ Health B Crit Rev 11: 301-321, 2008.
4. Vo C and Carney ME: Ovarian cancer hormonal and environmental risk effect. Obstet Gynecol Clin North Am 34: 687-700, viii, 2007.
5. Xie Y, Zhu J, Zhou XJ, Chen J, Lu NH and Wang CW: Expression of peroxisome proliferators-activated receptor-gamma and cyclooxygenase-2 in Helicobacter pylori infection-associated diseases and significance thereof. Zhonghua Yi Xue Za Zhi 86: 2683-2689, 2006 (In Chinese).
6. DuBois RN, Gupta R, Brockman J, Reddy BS, Krakow SL and Lazar MA: The nuclear eicosanoid receptor, PPARgamma, is aberrantly expressed in colonic cancers. Carcinogenesis 19: 49-53, 1998.
7. Jiang WG, Redfern A, Bryce RP and Mansel RE: Peroxisome proliferator activated receptor-gamma (PPAR-gamma) mediates the action of gamma linolenic acid in breast cancer cells. Prostaglandins Leukot Essent Fatty Acids 62: 119-127, 2000.
8. Wijnhoven BP, Lindstedt EW, Abbou M, Ijzendoorn Y, de Krijger RR, Tilanus HW and Dinjens WN; Rotterdam Esophageal Tumor Study Group: Molecular genetic analysis of the von Hippel-Lindau and human peroxisome proliferator-activated receptor gamma tumor-suppressor genes in adenocarcinomas of the gastroesophageal junction. Int J Cancer 94: 891-895, 2001.
9. Chang TH and Szabo E: Induction of differentiation and apoptosis by ligands of peroxisome proliferator-activated receptor gamma in non-small cell lung cancer. Cancer Res 60: 1129-1138, 2000.
10. Papi A, De Carolis S, Bertoni S, Storci G, Sceberras V, Santini D, Ceccarelli C, Taffurelli M, Orlandi M and Bonafe M: PPARα and RXR ligands disrupt the inflammatory cross-talk in the hypoxic breast cancer stem cells niche. J Cell Physiol 229: 1595-1606, 2014.
11. Chatterjee A, Kusunoki H, Taniyama Y, Rakugi H and Morishita R: Improvement of metabolic syndrome by irbesartan via the PPARα/HGF pathway in apolipoprotein E knockout mice. Biomed Rep 1: 65-70, 2013
12. Zukaszewicz-Zajc M, Mroczko B, Guziska-Ustymowicz K, Pryczynicz A, Gryko M, Kemona A, K-dra B and Szmitkowski M: Matrix metalloproteinase 2 (MMP-2) and their tissue inhibitor 2 (TIMP-2) in gastric cancer patients. Adv Med Sci 58: 235-243, 2013.
13. Waite LL, Louie RE and Taylor RN: Circulating activators of peroxisome proliferator-activated receptors are reduced in preeclamptic pregnancy. J Clin Endocrinol Metab 90: 620-626, 2005.
14. Liu J, Lu H, Huang R, Lin D, Wu X, Lin Q, Wu X, Zheng J, Pan X, Peng J, et al: Peroxisome proliferator activated receptor-gamma ligands induced cell growth inhibition and its influence on matrix metalloproteinase activity in human myeloid leukemia cells. Cancer Chemother Pharmacol 56: 400-408, 2005.
15. Balakumar P, Bishnoi HK and Mahadevan N: Telmisartan in the management of diabetic nephropathy: A contemporary view. Curr Diabetes Rev 8: 183-190, 2012.
16. Takagi H, Mizuno Y, Yamamoto H, Goto SN and Umemoto T; All-Literature Investigation of Cardiovascular Evidence Group: Effects of telmisartan therapy on interleukin-6 and tumor necrosis factor-alpha levels: A meta-analysis of randomized controlled trials. Hypertens Res 36: 368-373, 2013.
17. Lacourciere Y: Telmisartan or valsartan alone or in combination with hydrochlorothiazide: A review. Clin Exp Hypertens 35: 50-60, 2013.
18. Maejima Y, Okada H, Haraguchi G, Onai Y, Kosuge H, Suzuki J and Isobe M: Telmisartan, a unique ARB, improves left ventricular remodeling of infarcted heart by activating PPAR gamma. Lab Invest 91: 932-944, 2011.
19. Li J, Chen L, Yu P, Liu B, Zhu J and Yang Y: Telmisartan exerts anti-tumor effects by activating peroxisome proliferator-activated receptor.α in human lung adenocarcinoma A549 cells. Molecules 19: 2862-2876, 2014.
20. Shi M, Cao M, Song J, Liu Q, Li H, Meng F, Pan Z, Bai J and Zheng J: PinX1 inhibits the invasion and metastasis of human breast cancer via suppressing NF-κB/MMP-9 signaling pathway. Mol Cancer 14: 66, 2015.
21. Mozzetti S, Ferlini C, Concolino P, Filippetti F, Raspaglio G, Prislei S, Gallo D, Martinelli E, Ranelletti FO, Ferrandina G and Scambia G: Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients. Clin Cancer Res 11: 298-305, 2005.
22. Kamat AA, Kim TJ, Landen CN Jr, Lu C, Han LY, Lin YG, Merritt WM, Thaker PH, Gershenson DM, Bischoff FZ, et al: Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer. Cancer Res 67: 281-288, 2007.
23. de Araujo Junior RF, Leitao Oliveira AL, de Melo Silveira RF, de Oliveira Rocha HA, de Franca Cavalcanti P and de Araujo AA: Telmisartan induces apoptosis and regulates Bcl-2 in human renal cancer cells. Exp Biol Med (Maywood) 240: 34-44, 2015.
24. Koyama N, Nishida Y, Ishii T, Yoshida T, Furukawa Y and Narahara H: Telmisartan induces growth inhibition, DNA double-strand breaks and apoptosis in human endometrial cancer cells. PLoS One 9: e93050, 2014.
25. Auwerx J: PPARgamma, the ultimate thrifty gene. Diabetologia 42: 1033-1049, 1999.
26. Komar CM: Peroxisome proliferator-activated receptors (PPARs) and ovarian function-implications for regulating steroidogenesis, differentiation and tissue remodeling. Reprod Biol Endocrinol 3: 41, 2005.
27. Kolli V, Stechschulte LA, Dowling AR, Rahman S, Czernik PJ and Lecka-Czernik B: Partial agonist, telmisartan, maintains PPARα serine 112 phosphorylation, and does not affect osteoblast differentiation and bone mass. PLoS One 9: e96323, 2014.
28. Pang T, Sun LX, Wang T, Jiang ZZ, Liao H and Zhang LY: Telmisartan protects central neurons against nutrient deprivation-induced apoptosis in vitro through activation of PPARα and the Akt/GSK-3 β pathway. Acta Pharmacol Sin 35: 727-737, 2014.
29. Yiqin Y, Meilin X, Jie X and Keping Z: Aspirin inhibits MMP-2 and MMP-9 expression and activity through PPARalpha/gamma and TIMP-1. Mediated mechanisms in cultured mouse celiac macrophages. Inflammation 32: 233-241, 2009.
30. Funao K, Matsuyama M, Kawahito Y, Sano H, Chargui J, Touraine JL, Nakatani T and Yoshimura R: Telmisartan as a peroxisome proliferator-activated receptor.α ligand is a new target in the treatment of human renal cell carcinoma. Mol Med Rep 2: 193-198, 2009.
31. Zafiriou S, Stanners SR, Saad S, Polhill TS, Poronnik P and Pollock CA: Pioglitazone inhibits cell growth and reduces matrix production in human kidney fibroblasts. J Am Soc Nephrol 16: 638-645, 2005.
32. Araujo AA, Souza TO, Moura LM, Brito GA, Aragao KS, Araujo LS, Medeiros CA, Alves MS and Araujo RF Jr: Effect of telmisartan on levels of IL-1, TNF, down-regulated COX-2, MMP-2, MMP-9 and RANKL/RANK in an experimental periodontitis model. J Clin Periodontol 40: 1104-1111, 2013.
33. Yokota T, Osanai T, Hanada K, Kushibiki M, Abe N, Oikawa K, Tomita H, Higuma T, Yokoyama J, Hanada H and Okumura K: Effects of telmisartan on markers of ventricular remodeling in patients with acute myocardial infarction: Comparison with enalapril. Heart Vessels 25: 460-468, 2010.
34. Wu J, Lin H, Liu D, Liu J, Wang N, Mei X, Sun J, Yang G and Zhang X: The protective effect of telmisartan in Type 2 diabetes rat kidneys is related to the downregulation of thioredoxin-interacting protein. J Endocrinol Invest 36: 453-459, 2013.